New device aims to make clot removal safer for lung patients
NCT ID NCT07280247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a device that removes blood clots from the lungs of people with acute pulmonary embolism and then returns the cleaned blood back to their body. The goal is to see if this approach is safe and effective at reducing blood loss and complications. About 39 adults with intermediate-risk clots will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AlphaReturn Blood Management System (device that returns filtered blood to the body after clot removal)
- What this could lead to
- If successful, this could make clot removal safer by reducing blood loss and the need for transfusions in people with acute pulmonary embolism.
- What could go wrong
- This is a small early study with only 39 participants, so results may not apply to everyone. There is a risk of device-related complications like bleeding or injury to blood vessels.
Why investors are watching
AngioDynamics is testing its AlphaReturn blood management system alongside its cleared AlphaVac device in 39 patients with acute pulmonary embolism. For a small-cap company, this readout matters because it could expand the approved use of an existing product line, adding a new revenue source without a full new-device launch.
If it works: A positive safety and effectiveness result could support regulatory clearance for AlphaReturn in this setting, giving AngioDynamics a broader product story in clot removal. That could strengthen its position with hospitals and potentially open a larger market for its vascular devices.
If it fails: The trial could fail to show adequate safety or effectiveness, or enrollment and data collection could stall. Trials in small patient groups often miss their goals, and a negative result would likely limit AlphaReturn's use in pulmonary embolism and slow the company's growth plans.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 39 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: A potential subject will be included in the study if he/she meets all the following inclusion criteria: 1. Provision of signed and dated informed consent form. 2. Subject is 18 years of age and older. 3. Subject presents clinical signs and symptoms consistent with acute intermediate-risk pulmonary embolism for less than or equal to 14 days. 4. Subject has a diagnosis of pulmonary embolism detected from computed tomography angiography (CTA). 5. Subject has a RV/LV ratio of 0.9 or higher. 6. Subject has a systolic blood pressure (SBP) of 90mmHg or higher. 7. Subject has a heart rate of 130 beats per minute (BPM) or less prior to the procedure. 8. Subject is deemed medically eligible for interventional procedure(s) per institutional guidelines and/or clinical judgment. Exclusion Criteria: A potential subject will be excluded from the study if he/she meets any of the following exclusion criteria: 1. Subjects who are or may be pregnant as determined by a positive pregnancy test or who are breastfeeding. 2. Subjects who have any contraindication to systemic or therapeutic doses of heparin or anticoagulants. 3. Subjects who have used thrombolytics in the 30 days prior to the baseline CTA. 4. Subjects who have pulmonary hypertension with peak pulmonary artery pressure (PAP) \> 70 mmHg. 5. Subjects who have FiO2 requirement \> 44% or \> 6 LPM to keep oxygen saturations \> 90%. 6. Subjects with hematocrit \< 28% within 6 hours of index procedure. 7. Subjects with platelets count \< 100,000/μL. 8. Subjects with serum creatinine \> 1.8 mg/dL. 9. Subjects with International Normalized Ratio (INR) \> 3. 10. Subjects who have undergone a major trauma within the past 14 days of the index procedure and have Injury Severity Score (ISS) \> 15. 11. Subjects with the presence of cancer requiring active chemotherapy. 12. Subjects with known bleeding diathesis or coagulation disorder. 13. Subjects who have had a cardiovascular or pulmonary surgery within the past 7 days of index procedure. 14. Subjects with a history of severe or chronic pulmonary hypertension, uncompensated heart failure, chest irradiation, underlying lung disease that is oxygen dependent, heparin-induced thrombocytopenia (HIT) and/or chronic left heart disease with left ventricular ejection fraction ≤ 30%. 15. Subjects with known anaphylactic reaction to radiographic contrast agents that cannot be pretreated. 16. Subject requires vasopressor after fluids to keep pressure ≥ 90mmHg. 17. Subjects with left bundle branch block. 18. Subjects who have intracardiac lead in the right ventricle or atrium. 19. Evidence such as imaging or other that suggest the subject is not appropriate for this procedure. 20. Subjects that have life expectancy \< 90 days, in the opinion of the investigator at the time of enrollment. 21. Subjects dependent on extracorporeal life support such as extracorporeal membrane oxygenation (ECMO). 22. Participation in another investigational study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary embolism acute are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Baylor Heart Hospital Plano
RECRUITINGPlano, Texas, 75093, United States
-
CentraCare Heart and Vascular Center
RECRUITINGSaint Cloud, Minnesota, 56303, United States
-
Jacobi Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
-
Kettering Health
RECRUITINGKettering, Ohio, 45429, United States
-
Methodist Healthcare
RECRUITINGSan Antonio, Texas, 78229, United States
-
University at Buffalo
RECRUITINGBuffalo, New York, 14203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Clot-Removing device ease acute pulmonary embolism?
- Can a catheter device clear lung clots and ease heart strain?
- Which blood thinner is safer for lung clots? a Head-to-Head test
- Can a simple electrical scan spot dangerous lung clots without radiation?
- New suction device aims to quickly clear lung clots in emergency setting
- Blood test may spot hidden heart danger in lung clots